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EXTRASKELETAL INTRACRANIAL MESENCHYMAL
CHONDROSARCOMA: CASE REPORT AND
LITERATURE REVIEW
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We present the case of a 13-year-old girl with a huge intracranial mesenchymal chondrosarcoma. She had
suffered from severe headache, diplopia, intermittent nausea and vomiting for 1 month. Neurologic
examination revealed bilateral blurred optic disc margins and abducens paresis. Magnetic resonance
imaging demonstrated a giant, heterogeneous, intensely enhancing mass of 7 × 8 × 6 cm, occupying the
bilateral frontal and left high parietal regions and based on the anterior cerebral falx. A presumptive
diagnosis of aggressive meningioma was made. The patient underwent bicoronal craniotomy and gross
total resection of the tumor. Pathologic examination revealed an extraskeletal mesenchymal chondro-
sarcoma. She was under regular follow-up and remained free of recurrence after surgery. In addition to
the current case, we review previously reported cases of extraskeletal intracranial mesenchymal chondro-
sarcoma and discuss treatment strategies and outcomes.
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Primary sarcomas of the central nervous system are un-
common lesions. Mesenchymal chondrosarcoma represents
a very small subset of intracranial sarcomas, which by
themselves constitute less than 0.16% of primary intracra-
nial tumors [1,2]. Mesenchymal chondrosarcoma is a well-
defined tumor first described by Lichtenstein and Bern-
stein in 1959 [3], and later reported as a primary tumor in
extraosseous tissues, including the central nervous system
[4]. Intracranial mesenchymal chondrosarcoma is a rare en-
tity. To the best of our knowledge, only 36 cases have been
reported in the English literature.
Here, we describe the case of a 13-year-old girl who had
headache, diplopia, nausea, and vomiting. Computerized
tomography (CT) of the brain revealed an anterior falx-
based extraskeletal intracranial mesenchymal chondrosar-
coma that was initially thought to be a malignant meningio-
ma. We present CT, magnetic resonance imaging (MRI),
and light microscopy results for this aggressive tumor. The
treatment strategies are provided after a review of the
literature.
CASE PRESENTATION
This 13-year-old girl, a native of Taiwan, was referred to our
hospital in December 2000 with a 1-month history of blurred
vision, nausea, vomiting, and intermittent headache. These
were associated with diplopia and right hemiparesis. Her
past medical history was unremarkable. She was initially
brought to the ophthalmologic clinic for help, where bilateral
optic disc swelling was noted. Brain CT demonstrated an
enhanced mass lesion over bilateral frontal lobes (Figure 1).
Severe mass effect, perifocal edema, and collapse of the left
lateral ventricle were also noted. The patient was thus re-
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ferred to our neurosurgical clinic for further evaluation.
Neurologic examination elicited several positive
findings, including bilateral abducens palsy and decreased
muscle power of right limbs to grade IV. The patient’s con-
sciousness was clear and no sensory deficit was detected.
Coordination was intact. Results of the rest of the physical
examination were normal.
Gadolinium-enhanced MRI of the brain demonstrated a
multilobulated giant heterogeneous mass lesion of about
7 × 8 × 6 cm, based on the anterior cerebral falx, occupying
the bilateral frontal lobes and left high parietal lobe with
intense enhancement (Figure 2). This mass and associated
severe perifocal edema resulted in compression of bilateral
lateral ventricles, the third ventricle, left thalamus, and left
basal ganglia. A preoperative presumptive diagnosis of ag-
gressive meningioma, or possibly hemangiopericytoma,
was made.
The patient underwent bicoronal craniotomy on Decem-
ber 28, 2000. Gross total resection of the tumor was per-
formed. The tumor was multilobulated and attached to the
anterior cerebral falx. Grossly, it was reddish-brown and
rubbery hard. The main part of the tumor was located in the
left frontal lobe with partial erosion of the anterior cerebral
falx and extension into the right frontal and left parietal
lobes. Loose adhesion between the tumor and the neigh-
boring falx was noted. There was no evidence of invasion
to the dura or skull bone. The postoperative course was
smooth except for transient diabetes insipidus for 3 days
that subsided without adverse postoperative sequelae.
Light microscopic examination of the tumor specimen
demonstrated a bimorphic pattern (Figure 3A). The tumor
was composed of undifferentiated round or spindle-shaped
cells and islets of cartilaginous tissue. The primitive undif-
ferentiated cells possessed round or ovoid hyperchromatic
nuclei and scanty, poorly outlined, eosinophilic cytoplasm
(Figure 3B). They were arranged in a hemangiopericyto-
matous pattern around the vascular cleft. The cartilagi-
nous foci were generally well defined. There was often an
abrupt transition between the cartilaginous and undiffer-
entiated areas. In addition, occasional areas of necrosis or
hemorrhage were seen. Immunohistochemical examination
of the cartilaginous portion of the tumor was positive for
S-100 protein (Figure 3C). The undifferentiated tumor cells
were positive for vimentin but negative for glial fibrillary
acidic protein, neuron-specific enolase, and cytokeratin. A
pathologic diagnosis of extraskeletal mesenchymal chondro-
sarcoma was made.
Postoperatively, the neurologic deficit was in complete
remission. The patient was discharged home 11 days after
surgery without postoperative adjuvant radiotherapy or
chemotherapy. Her school performance was much improved
in the follow-up period. Serial MRI studies revealed no
evidence of recurrence 30 months after surgery (Figure 4).
DISCUSSION
Mesenchymal chondrosarcoma is a high-grade malignant
neoplasm with a very high tendency to local recurrence and
Figure 1. Pre- and post-contrast computerized tomography scans
demonstrate a well-enhanced mass lesion over the bilateral frontal
regions, with perifocal edema and collapse of the left ventricle.
Figure 2. Preoperative gadolinium-
enhanced, T1-weighted magnetic
resonance images demonstrating the
bifrontal tumor mass with strongly
intense enhancement: (A) axial view;
(B) coronal view; (C) sagittal view.
B A C
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distant metastasis [5,6]. It was first described as an unusual
malignant neoplasm arising from bone that resembles
primitive cartilaginous mesenchyme. After the first re-
port of an extraskeletal intracranial mesenchymal
chondrosarcoma in 1962 by Dahlin and Henderson [7],
there were 37 cases reported in the English literature (Ta-
ble) [5–25]. Most extraskeletal intracranial mesenchymal
chondrosarcomas have been reported in patients in their
second or third decade of life, with a slight female pre-
ponderance [2,13,19,26]. The most common location of this
tumor in the central nervous system is the craniospinal
meninges [6]. Typically, such tumors are supratentorial,
most often found in the frontoparietal region, and are at-
tached to the meninges. Sometimes, the tumor may closely
resemble a hemangiopericytoma or a cartilage-containing
meningioma under light microscopy, especially when a
limited amount of biopsy specimen that does not contain
the cartilaginous elements is provided to the pathologist
[27].
An intracranial mesenchymal chondrosarcoma can be
very difficult to differentiate from a meningioma by radio-
logic studies. The tumors are hypointense to normoin-
tense on T1-weighted MRI and have strong enhancement.
They can resemble malignant meningioma or hemangio-
pericytoma. These lesions are extremely hypervascular
on angiographic examination, and embolization may be
necessary before surgery [13,16].
On pathologic examination, the tumor is usually well
circumscribed, rubbery firm, multilobulated, reddish-brown
or gray, and often invasive. The cut surface is bloody with
prominent vascularity and focal calcification. Microscopic
examination shows some specific characteristics. The tu-
mor has two distinct components: highly cellular and
undifferentiated mesenchymal cells on the one hand, and
islands of well-differentiated, benign-appearing cartilage
on the other. The transition between these two components
is frequently abrupt. Immunohistochemically, mesenchymal
cells stain positive for vimentin but negative for glial fibrillary
acidic protein and neuron-specific enolase. The chondroid
cells stain positive for S-100 protein. Therefore, mesenchymal
chondrosarcoma can be differentiated from meningioma
or hemangiopericytoma largely by light microscopy and
specific immunohistochemical staining.
The origin of the tumor is still under investigation. It
was thought to originate from the embryonal cartilaginous
rests in the cranial bones and dura, from the meningeal
fibroblasts, or from the multipotent mesenchymal cells
in the dura or arachnoid [28,29]. The latter theory is more
popular. One study even indicated that mesenchymal chon-
drosarcoma was the neoplasm of differentiating premesen-
chymal chondroprogenitor cells [30]. Such early mesen-
chymal precursor cells are not restricted to bone but are
found throughout the body.
Figure 3. Histology of the tissue sample: (A) bimorphic nature of the
tumor, comprising undifferentiated round or spindle-shaped cells and
islets of cartilaginous tissue (hematoxylin & eosin, × 100); (B) round or
spindle-shaped undifferentiated cells (hematoxylin & eosin, × 400);
(C) chondroid cells stain positive (red) for S-100 protein (× 400).
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Figure 4. Postoperative gadolinium-
enhanced, T1-weighted magnetic re-
sonance images 2 years after surgery;
there is no residual tumor or recur-
rence: (A) axial view; (B) coronal view;
(C) sagittal view.
B A C
Table. Clinical features of cases of extraskeletal intracranial mesenchymal chondrosarcoma published in the English literature
Age/gender Location/attachment Treatment Outcome (postoperative) Reference
44 yr /F Rt parietal/dura GTR Died, 108 mo (9 REC) [7]
11 yr /M Frontal/parenchyma GTR Alive, 5 mo [8]
48 yr /F Rt frontal/parenchyma R Died, 3 d [9]
18 yr /F Frontal/dura STR Died, 16 mo (4 REC) [10]
51 yr /F Rt parietal/dura STR, XRT Died, 11 mo (1 REC, Mt) [11]
13 yr /M Rt frontoparietal/dura GTR Alive, 18 mo [12]
19 yr /M Parietal/dura R, XRT Alive, 12 mo (1 REC) [13]
19 yr /M Occipital/dura GTR Unknown [14]
7 yr /M Rt temporal/dura R Alive, 84 mo (1 REC) [6]
17 yr /F Frontal/dura R Died, 24 mo [6]
40 yr /M Convexity/dura R Died, 5 d [6]
11 yr /M Lt parietooccipital/dura STR Alive, 96 mo (1 REC, Mt) [15]
33 yr /M Lt frontal/dura R Alive, 36 mo (2 REC) [16]
26 yr /F Parasagittal/dura GTR Died, 3 d [16]
23 yr /F Rt parietal/dura R, XRT Alive, 54 mo [16]
26 yr /F Lt cerebellar/parenchyma R Alive, 30 mo [16]
22 yr /M Cerebellar/parenchyma R Died, 4 mo (1 REC) [5]
21 yr /F Frontal/dura R Died, 84 mo (Mt) [13]
11 mo /M Rt frontal R, XRT Died, unknown [17]
12 yr /F Prefrontal R, C, XRT Died, unknown (1 REC) [17]
61 yr /F Rt parietal/dura R, XRT Alive, unknown [18]
6 yr /F Thalamus/parenchyma None Died, 96 mo [19]
11 yr /F Lt parietal/parenchyma R, XRT Died, 18 mo (1 REC) [20]
13 yr /F Lt frontoparietal/dura GTR Alive, 36 mo (1 REC) [21]
5 yr /M Frontal/dura GRT, XRT Alive, 14 mo [22]
7 yr /F Sphenoid ridge/dura STR Died, 60 mo (Mt) [22]
11 yr /F Frontal STR, XRT Died, 20 mo (Mt) [22]
13 yr /F Sphenoid ridge/dura GTR Alive, 15 mo [22]
15 yr /M Parasagittal/parenchyma STR, XRT Died, 72 mo (1 REC) [22]
17 yr /F Anterior skull base GTR, XRT Died, 84 mo (Mt) [22]
45 yr /M Meckel’s cave GTR, XRT Alive, 28 mo [22]
68 yr /M Parasagittal GTR, XRT Died, 120 mo [22]
8 yr /M Cerebellar/parenchyma GTR, XRT, C Alive, 18 mo (Mt) [23]
24 yr /F Frontal/dura GTR, XRT Alive, 18 mo [24]
6 mo /M Rt frontoparietal/dura GTR, C Died, 2 mo (1 REC) [24]
17 yr /F Rt parietal/parenchyma GTR, XRT Died, 4 mo (2 REC) [25]
13 yr /F Bifrontal/falx GTR Alive, 30 mo Present case
F = female; Rt = right; GTR = gross total resection; REC = recurrence; M = male; R = resection; STR = subtotal resection; XRT = radiotherapy;
Mt = metastasis; Lt = left; C = chemotherapy.
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Mesenchymal chondrosarcomas have not been very
well characterized cytogenetically, partly because the chro-
mosomal aberrations reported are usually complex and
heterogeneous. Sainati et al suggested a histogenetic rela-
tionship between mesenchymal chondrosarcoma, Ewing
sarcoma, and primitive neuroectodermal tumor, with the
observation of a translocation of chromosomes 11 and 22
in all three categories of tumor [31]. Szymanska et al reported
an extraskeletal mesenchymal chondrosarcoma with
clonal aberrations such as t(1;20)(q21;q13), t(4;9)(q23,q22),
and loss of chromosomes 4, 21, and 22 in the metaphase
[32]. Naumann et al reported one skeletal and one extra-
skeletal mesenchymal chondrosarcoma with an identical
Robertsonian translocation, der(13;21)(q10;q10) [33]. Both
cases also exhibited loss of all or a portion of chromo-
somes 8 and 20, and gain of all or a portion of chromo-
some 12. If additional studies confirm these data, this
might lead to the identification of the genes central to the
neoplastic process.
Extraskeletal mesenchymal chondrosarcoma has a high
tendency to be locally aggressive, with recurrence; it is the
most malignant subtype of chondrosarcoma [1]. The 5-year
survival rate has been reported to range from 42% to 68%,
and the 10-year survival rate from 28% to 32% [15,34]. The
tumor has the propensity not only for local recurrence but
also for distant metastasis. It can metastasize to the lum-
bar vertebrae [15], the ribs [13], and to the heart and several
intra-abdominal organs [11]. One patient developed lepto-
meningeal dissemination of the tumor after treatment
[23].
Among the reported cases, 20 patients died 3 days to 9
years after surgery (mean, 40 months). Fourteen patients
had recurrence after surgery, while nine patients did not
have recurrence 5 months to 4.5 years (mean, 23 months)
after surgical resection. Our patient experienced no evidence
of recurrence for at least 30 months after surgery. Diplopia
and muscle weakness subsided considerably. No major
neurologic deficit persisted after surgery. Her performance
in junior high school was much improved.
The optimal treatment for extraskeletal intracranial
mesenchymal chondrosarcoma is radical surgical excision
of the tumor, if possible [4,28,35]. Some authors recommend
that radiotherapy with or without concomitant chemo-
therapy should be considered for treatment of patients with
unresectable mesenchymal chondrosarcoma and for those
in whom the surgical margins are inadequate after radical
surgical excision [5]. However, the potential benefits of
radiotherapy and chemotherapy remain controversial
because of the rarity of the tumor.
CONCLUSION
Extraskeletal intracranial mesenchymal chondrosarcoma is
a rare malignant tumor, with a strong tendency to local ag-
gression and distant metastasis. It occurs mainly in young
adulthood and can be mistaken for a meningioma or
hemangiopericytoma on radiologic studies. Thus, this
aggressive tumor should be considered in the differential
diagnosis of an enhancing mass in the frontoparietal re-
gion, especially in adolescent and young adult patients. A
sufficient biopsy specimen should be obtained due to the
biphasic nature of the tumor; limited specimen size may
result in misdiagnosis. The mainstay of treatment is aggres-
sive radical resection, if possible, with close postoperative
follow-up, because it offers the greatest opportunity for a
long-term, recurrence-free period for patients, although
the long-term outcomes may be disappointing. Radio-
therapy and chemotherapy may be considered to reduce the
risk of recurrence, or to treat patients with unresectable
tumors and for those in whom the surgical margins are
inadequate after radical surgery. However, the benefits of
radiotherapy and chemotherapy are unclear and further
investigation is necessary.
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